JP2020122012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020122012A5 JP2020122012A5 JP2020082487A JP2020082487A JP2020122012A5 JP 2020122012 A5 JP2020122012 A5 JP 2020122012A5 JP 2020082487 A JP2020082487 A JP 2020082487A JP 2020082487 A JP2020082487 A JP 2020082487A JP 2020122012 A5 JP2020122012 A5 JP 2020122012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug
- concentration
- benzodiazepine
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 claims 44
- 239000003814 drug Substances 0.000 claims 44
- 238000000034 method Methods 0.000 claims 30
- 239000000611 antibody drug conjugate Substances 0.000 claims 28
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 28
- 229940049706 benzodiazepine Drugs 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 21
- 239000000562 conjugate Substances 0.000 claims 6
- -1 benzodiazepine compound Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims 2
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- DOKWDOLZCMETIJ-ZAQUEYBZSA-N (12as)-9-[[3-[[(12as)-8-methoxy-6-oxo-11,12,12a,13-tetrahydroindolo[2,1-c][1,4]benzodiazepin-9-yl]oxymethyl]-5-[2-[2-(2-methoxyethoxy)ethoxy]ethyl-(2-methyl-2-sulfanylpropyl)amino]phenyl]methoxy]-8-methoxy-12a,13-dihydroindolo[2,1-c][1,4]benzodiazepin-6-o Chemical compound N1=C[C@@H]2CC3=CC=CC=C3N2C(=O)C(C=C2OC)=C1C=C2OCC1=CC(N(CC(C)(C)S)CCOCCOCCOC)=CC(COC=2C(=CC=3C(=O)N4C5=CC=CC=C5C[C@H]4CNC=3C=2)OC)=C1 DOKWDOLZCMETIJ-ZAQUEYBZSA-N 0.000 claims 1
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims 1
- FYKCKCYYMXDNHZ-UHFFFAOYSA-N 2-sulfobutanoic acid Chemical compound CCC(C(O)=O)S(O)(=O)=O FYKCKCYYMXDNHZ-UHFFFAOYSA-N 0.000 claims 1
- 229940126161 DNA alkylating agent Drugs 0.000 claims 1
- 239000012624 DNA alkylating agent Substances 0.000 claims 1
- 230000000970 DNA cross-linking effect Effects 0.000 claims 1
- 239000012623 DNA damaging agent Substances 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 229940122429 Tubulin inhibitor Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical group N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462044592P | 2014-09-02 | 2014-09-02 | |
| US62/044,592 | 2014-09-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511615A Division JP2017526682A (ja) | 2014-09-02 | 2015-09-02 | 抗体薬物複合体組成物の製剤化方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020122719A Division JP2020172541A (ja) | 2014-09-02 | 2020-07-17 | 抗体薬物複合体組成物の製剤化方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020122012A JP2020122012A (ja) | 2020-08-13 |
| JP2020122012A5 true JP2020122012A5 (cg-RX-API-DMAC7.html) | 2020-09-24 |
Family
ID=55401285
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511615A Withdrawn JP2017526682A (ja) | 2014-09-02 | 2015-09-02 | 抗体薬物複合体組成物の製剤化方法 |
| JP2020082487A Pending JP2020122012A (ja) | 2014-09-02 | 2020-05-08 | 抗体薬物複合体組成物の製剤化方法 |
| JP2020122719A Withdrawn JP2020172541A (ja) | 2014-09-02 | 2020-07-17 | 抗体薬物複合体組成物の製剤化方法 |
| JP2022010024A Withdrawn JP2022050688A (ja) | 2014-09-02 | 2022-01-26 | 抗体薬物複合体組成物の製剤化方法 |
| JP2024058979A Active JP7789826B2 (ja) | 2014-09-02 | 2024-04-01 | 抗体薬物複合体組成物の製剤化方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511615A Withdrawn JP2017526682A (ja) | 2014-09-02 | 2015-09-02 | 抗体薬物複合体組成物の製剤化方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020122719A Withdrawn JP2020172541A (ja) | 2014-09-02 | 2020-07-17 | 抗体薬物複合体組成物の製剤化方法 |
| JP2022010024A Withdrawn JP2022050688A (ja) | 2014-09-02 | 2022-01-26 | 抗体薬物複合体組成物の製剤化方法 |
| JP2024058979A Active JP7789826B2 (ja) | 2014-09-02 | 2024-04-01 | 抗体薬物複合体組成物の製剤化方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20160058884A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3311846A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2017526682A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240011258A (cg-RX-API-DMAC7.html) |
| CN (3) | CN113842468B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015311951B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2958882A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1254612A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL250768B (cg-RX-API-DMAC7.html) |
| MA (2) | MA42561A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2741470C9 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201701328XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016036861A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
| PL3038650T3 (pl) | 2013-08-30 | 2021-11-22 | Immunogen, Inc. | Przeciwciała i testy do wykrywania receptora folianu 1 |
| CA2958882A1 (en) * | 2014-09-02 | 2016-03-10 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
| SI3313845T1 (sl) * | 2015-06-29 | 2021-01-29 | Immunogen, Inc. | Konjugati spremenjenih protiteles cisteina |
| CA3026504A1 (en) | 2016-06-07 | 2017-12-14 | Nanopharmaceuticals, Llc | Non-cleavable polymer conjugated with .alpha..nu..beta.3 integrin thyroid antagonists |
| WO2018085359A1 (en) * | 2016-11-02 | 2018-05-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
| MA46887A (fr) | 2016-11-23 | 2019-10-02 | Immunogen Inc | Sulfonation sélective de dérivés de benzodiazépine |
| CA3087993A1 (en) * | 2018-01-12 | 2019-07-18 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
| US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| KR102788989B1 (ko) | 2019-02-15 | 2025-03-31 | 우시 엑스디씨 싱가포르 프라이빗 리미티드 | 동질성이 개선된 항체-약물 콘쥬게이트의 제조방법 |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| CN114222756A (zh) | 2019-04-29 | 2022-03-22 | 伊缪诺金公司 | 双互补位FR-α抗体和免疫缀合物 |
| US20220373558A1 (en) * | 2019-09-19 | 2022-11-24 | Janssen Biotech, Inc. | Materials and methods for differential characterization of molecular conjugates and conjugation |
| US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
| US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DK0563475T3 (da) | 1992-03-25 | 2000-09-18 | Immunogen Inc | Konjugater af cellebindende midler og derivater af CC-1065 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| ATE200679T1 (de) | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| US6995145B1 (en) * | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| GB0202319D0 (en) | 2002-02-01 | 2002-03-20 | Calex Electronics Ltd | Apparatus |
| KR20050010756A (ko) * | 2002-02-22 | 2005-01-28 | 뉴 리버 파마슈티칼스, 인크. | 피험자 간 약물 혈청 농도의 변동성을 감소시키기 위한펩티드-약물 접합체의 용도 |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| PT1578446E (pt) | 2002-11-07 | 2015-07-22 | Immunogen Inc | Anticorpos anti-cd33 e processo para tratamento de leucemia mieloide aguda usando os mesmos |
| MX369959B (es) * | 2003-05-14 | 2019-11-27 | Immunogen Inc | Composicion de farmaco conjugado. |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| AU2004240541B2 (en) | 2003-05-20 | 2009-08-20 | Immunogen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| BRPI0412879A8 (pt) | 2003-07-21 | 2015-12-15 | Immunogen Inc | Conjugado citotóxico específico do antígeno ca6 e métodos de seu uso |
| US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
| RU2404810C9 (ru) | 2004-06-01 | 2015-06-20 | Дженентек, Инк. | Конъюгаты антитело-лекарственное средство и способы |
| ES2539126T3 (es) * | 2004-12-09 | 2015-06-26 | Janssen Biotech, Inc. | Inmunoconjugados anti integrina, métodos para su producción y su uso |
| US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| US8156876B2 (en) | 2005-06-23 | 2012-04-17 | Georgia Tech Research Corporation | Systems and methods for integrated plasma processing of waste |
| EP1917034A4 (en) | 2005-08-22 | 2009-04-29 | Immunogen Inc | CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHOD OF ITS APPLICATION |
| WO2007024536A2 (en) * | 2005-08-24 | 2007-03-01 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
| SI1813614T1 (sl) * | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| WO2007092772A2 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
| PT2032606E (pt) * | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| WO2008070593A2 (en) * | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| US20090163698A1 (en) * | 2007-05-11 | 2009-06-25 | John Joseph Grigsby | Method for Preparing Antibody Conjugates |
| US7576505B2 (en) * | 2007-06-21 | 2009-08-18 | Jack Chen | Device for finding a home position for a moveable member |
| US20090208979A1 (en) * | 2008-02-14 | 2009-08-20 | Technion Research And Development Foundation Ltd. | Method for identifying antipsychotic drug candidates |
| KR20230003298A (ko) | 2008-04-30 | 2023-01-05 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| BRPI1013990A2 (pt) * | 2009-05-06 | 2019-04-30 | Biotest Ag | método para tratar uma doença , e, combinação anticâncer |
| AR078470A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| EP2486023A4 (en) * | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| RS55738B1 (sr) | 2010-02-24 | 2017-07-31 | Immunogen Inc | Imunokonjugati protiv folatnog receptora 1 i njihove upotrebe |
| EP3620467A1 (en) | 2010-03-12 | 2020-03-11 | Debiopharm International SA | Cd37-binding molecules and immunoconjugates thereof |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| MX2013004761A (es) | 2010-10-29 | 2013-08-27 | Immunogen Inc | Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas. |
| DK2675480T3 (en) * | 2011-02-15 | 2019-04-15 | Immunogen Inc | PROCEDURES FOR PREPARING CONJUGATES |
| BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
| MX2013011385A (es) * | 2011-04-01 | 2014-03-13 | Immunogen Inc | Moleculas de union a cd37 y sus inmunoconjugados. |
| WO2012138749A1 (en) | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Methods for decreasing ocular toxicity of antibody drug conjugates |
| WO2012177837A2 (en) | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| JO3625B1 (ar) | 2011-09-22 | 2020-08-27 | Amgen Inc | بروتينات رابطة للأنتيجين cd27l |
| MX2014006087A (es) | 2011-11-21 | 2014-08-01 | Immunogen Inc | Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico. |
| MX359599B (es) * | 2012-10-04 | 2018-09-12 | Immunogen Inc | Uso de una membrana de pvdf para purificar conjugados de agentes de unión celular y agentes citotóxicos. |
| AU2013349733C1 (en) * | 2012-11-20 | 2020-10-01 | Sanofi | Anti-CEACAM5 antibodies and uses thereof |
| LT2958944T (lt) * | 2013-02-22 | 2019-07-10 | Abbvie Stemcentrx Llc | Antikūno prieš dll3 ir pbd konjugatai bei jų panaudojimas |
| MX2016001541A (es) * | 2013-08-02 | 2016-08-18 | Sanofi Sa | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. |
| CA2958882A1 (en) * | 2014-09-02 | 2016-03-10 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
| EP3188733B1 (en) * | 2014-09-03 | 2019-11-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| SG11201701455SA (en) * | 2014-09-03 | 2017-03-30 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
| WO2016036804A1 (en) * | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| JP2016052860A (ja) | 2014-09-04 | 2016-04-14 | 株式会社東海理化電機製作所 | タイヤ位置登録システム |
-
2015
- 2015-09-02 CA CA2958882A patent/CA2958882A1/en active Pending
- 2015-09-02 CN CN202110769825.XA patent/CN113842468B/zh active Active
- 2015-09-02 SG SG11201701328XA patent/SG11201701328XA/en unknown
- 2015-09-02 EP EP17001799.0A patent/EP3311846A1/en active Pending
- 2015-09-02 CN CN201580047269.8A patent/CN106999604B/zh active Active
- 2015-09-02 MA MA042561A patent/MA42561A/fr unknown
- 2015-09-02 KR KR1020247001597A patent/KR20240011258A/ko active Pending
- 2015-09-02 US US14/843,769 patent/US20160058884A1/en not_active Abandoned
- 2015-09-02 EP EP15837813.3A patent/EP3188761A4/en not_active Withdrawn
- 2015-09-02 WO PCT/US2015/048152 patent/WO2016036861A1/en not_active Ceased
- 2015-09-02 AU AU2015311951A patent/AU2015311951B2/en active Active
- 2015-09-02 CN CN201810117483.1A patent/CN109147874A/zh active Pending
- 2015-09-02 MA MA040539A patent/MA40539A/fr unknown
- 2015-09-02 RU RU2017107873A patent/RU2741470C9/ru active
- 2015-09-02 JP JP2017511615A patent/JP2017526682A/ja not_active Withdrawn
- 2015-09-02 KR KR1020177008946A patent/KR102626976B1/ko active Active
-
2017
- 2017-02-26 IL IL250768A patent/IL250768B/en active IP Right Grant
- 2017-08-16 US US15/678,505 patent/US10603388B2/en not_active Expired - Fee Related
-
2018
- 2018-10-23 HK HK18113578.3A patent/HK1254612A1/en unknown
-
2019
- 2019-05-09 US US16/407,384 patent/US20190365917A1/en not_active Abandoned
-
2020
- 2020-05-08 JP JP2020082487A patent/JP2020122012A/ja active Pending
- 2020-07-17 JP JP2020122719A patent/JP2020172541A/ja not_active Withdrawn
-
2021
- 2021-06-07 IL IL283777A patent/IL283777A/en unknown
- 2021-06-17 AU AU2021204047A patent/AU2021204047B2/en active Active
-
2022
- 2022-01-26 JP JP2022010024A patent/JP2022050688A/ja not_active Withdrawn
- 2022-12-23 US US18/146,307 patent/US20230364252A1/en active Pending
-
2024
- 2024-04-01 JP JP2024058979A patent/JP7789826B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020122012A5 (cg-RX-API-DMAC7.html) | ||
| JP2024079825A5 (cg-RX-API-DMAC7.html) | ||
| JP2017526682A5 (cg-RX-API-DMAC7.html) | ||
| Jain et al. | Current ADC linker chemistry | |
| Skidmore et al. | ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1–resistant breast and gastric cancers | |
| Yurkovetskiy et al. | A polymer-based antibody–vinca drug conjugate platform: Characterization and preclinical efficacy | |
| US9114179B2 (en) | Immunoconjugate formulations | |
| Yang et al. | Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery | |
| RU2017107873A (ru) | Способы составления композиций конъюгата антитело-лекарственное средство | |
| Forte et al. | Homogeneous antibody-drug conjugates via site-selective disulfide bridging | |
| Krall et al. | Small targeted cytotoxics: current state and promises from DNA‐encoded chemical libraries | |
| Senter et al. | Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates | |
| Alley et al. | The pharmacologic basis for antibody-auristatin conjugate activity | |
| Venditto et al. | Cancer nanomedicines: so many papers and so few drugs! | |
| Jeffrey et al. | Dipeptide-based highly potent doxorubicin antibody conjugates | |
| Doronina et al. | Development of potent monoclonal antibody auristatin conjugates for cancer therapy | |
| HRP20191688T1 (hr) | Cd37-vezujuće molekule i njihovi imunokonjugati | |
| JP2021516960A5 (cg-RX-API-DMAC7.html) | ||
| Singh et al. | A new triglycyl peptide linker for antibody–drug conjugates (ADCs) with improved targeted killing of cancer cells | |
| Albers et al. | Exploring the effects of linker composition on site-specifically modified antibody–drug conjugates | |
| Singh et al. | Antibody–cytotoxic agent conjugates: preparation and characterization | |
| JP2013506709A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Metabolism of bioconjugate therapeutics: why, when, and how? | |
| Wang et al. | Disulfide linkage: a potent strategy in tumor-targeting drug discovery | |
| Gilad et al. | “Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide |